- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06307964
Intra-Hepatic Microbiota in Alcoholic Hepatitis (HepMAH)
Alcoholic hepatitis (AH) is a serious complication of alcoholic liver disease (ALD). The histological presentation of AH is characterized by neutrophilic lobular inflammation, macrovesicular steatosis, hepatocyte ballooning and necrosis and the presence of Mallory bodies. In cases of severe HA, defined by a modified Maddrey score of 32 or above, mortality at 1 month is estimated at between 10 and 50%. The only treatment to reduce early mortality is corticosteroid therapy. However, only 60% of patients respond to corticosteroids, and no benefit has been demonstrated on late mortality. Identifying new therapeutic targets is therefore a major challenge in this disease.
Numerous pre-clinical studies and human data suggest the involvement of the intestinal microbiota in the pathogenesis of AH. Translocation of viable bacteria and microbial products from the digestive tract to the liver contributes to local and systemic inflammation, hepatocyte death and fibrogenesis. However, the intrahepatic microbial environment has never been characterized in HA.
The study hypothesis is that the intrahepatic microbiota is modulated by bacterial translocation and is associated with clinical outcomes.
The aim of this study is to determine the composition of the intrahepatic (obtained from transjugular liver biopsy), blood and fecal microbiota in patients with suspected severe AH from a monocentric prospective cohort in the Hepatology Department at Croix-Rousse Hospital (Lyon). Fifty consecutive patients with clinical suspicion of AH and indication for transjugular liver biopsy will be included. About thirty-five patients are expected in the confirmed AH group, and 15 in the group "alcoholic liver disease with no AH", based on data from the literature. The composition of the various microbiota will be determined by sequencing the 16S rRNA gene, and the results will be correlated with clinical data (corticosteroid sensitivity, overall survival, transplant-free survival, MELD score in particular) and histological data.
This exploratory study will enable to analyze the intra-hepatic microbiota, and to study its link with intra-hepatic inflammation and the clinical course of patients with AH. The data generated by HepMAH will thus help identify potential new therapeutic targets linked to the gut microbiota, and provide a scientific basis for the development of therapeutic interventions targeting the microbiota in HA.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Yasmina CHOUIK, M.D., Ph.D.
- Phone Number: +33426109204
- Email: yasmina.chouik@chu-lyon.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
A prospective observational multicentric cohort will be conducted at Croix Rousse Hospital (Lyon, France), in the Hepatology and Intensive Care Units.
Fifty consecutive patients hospitalized in either of these units for clinical suspicion of alcoholic hepatitis and indication for transjugular liver biopsy will be included.
Description
Inclusion Criteria:
- Patients suffering from alcoholic liver disease and clinical suspicion of alcoholic hepatitis (subacute jaundice, heavy alcohol consumption active or weaned for ≤ 3 months, modified Maddrey score ≥32) and indication for diagnostic transjugular liver biopsy;
- Non-objection obtained from the patient or trusted person in case of impaired judgment or consciousness before performing liver biopsy;
- Aged ≥ 18 years at the time of study entry;
Exclusion Criteria:
- Patients who have been treated with antibiotics or probiotics within the last 15 days prior to liver biopsy, with the exception of antibiotics used for prophylaxis of ascites infection or hepatic encephalopathy
- Contraindication to transjugular liver biopsy (hepatocellular carcinoma on predicted puncture site)
- Pregnant, parturient or breast-feeding women
- Persons deprived of their liberty by judicial or administrative decision
- Adults under legal protection (guardianship, curators)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Alcoholic hepatitis
Patients with histologically proven AH (after transjugular liver biopsy procedure and histological assessment).
|
|
No alcoholic hepatitis
Patients with initially suspected AH (excessive alcohol consumption and modified Maddrey score > 32) but no AH at the histological evaluation of liver biopsy. It corresponds to patients with decompensated alcoholic liver disease but no AH. |
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Microbiota composition
Time Frame: At Day 0, 1 month and 6 months
|
Intrahepatic, blood and fecal microbiota composition will be assessed by 16S rRNA sequencing (MiSeq Illumina). Microbiota analysis will be performed on the fragment of transjugular liver biopsy collected for the purpose of the study, and on plasma and fecal samples after bacterial DNA extraction. Bioinformatics analysis will be carried out using Qiime2, LeFSE (Conda) and the Maaslin2 package (v3.16; R software). Microbiota profiles determined at the genus taxonomic level will be compared between the two groups (proven AH and no AH). |
At Day 0, 1 month and 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Yasmina CHOUIK, M.D., Ph.D., Hospices Civils de Lyon, Croix Rousse Hospital, Hepatology department
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Digestive System Diseases
- Pathologic Processes
- Alcohol-Related Disorders
- Substance-Related Disorders
- RNA Virus Infections
- Virus Diseases
- Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Alcohol-Induced Disorders
- Liver Diseases
- Fibrosis
- Hepatitis
- Hepatitis A
- Hepatitis, Alcoholic
- Liver Diseases, Alcoholic
Other Study ID Numbers
- 69HCL23_1137
- ID-RCB (Other Identifier: ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cirrhosis
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
University Health Network, TorontoUnknown
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingPrimary Biliary CirrhosisChina
-
Northwestern UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
National Institute of Diabetes and Digestive and...National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
Indiana UniversityNot yet recruiting
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruitingDecompensated CirrhosisIndia
-
Milton S. Hershey Medical CenterNot yet recruitingCirrhosis, Liver
-
Beijing 302 HospitalWuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, ChinaNot yet recruitingDecompensated CirrhosisChina
-
The Cleveland ClinicRecruiting
Clinical Trials on Biological sampling
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
Centre Hospitalier Universitaire de NīmesCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
-
University Hospital, ToursRecruitingAcute Lymphoid Leukemia | Acute Myeloid Leukemia in ChildrenFrance
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingPeriodontitis | Trisomy 21France
-
Institut Paoli-CalmettesAstraZenecaRecruiting
-
University Hospital, BordeauxNot yet recruitingMyelodysplastic Syndromes | FerroptosisFrance
-
Luxembourg Institute of HealthCentre Hospitalier du Luxembourg; University of Luxembourg; Laboratoire National... and other collaboratorsRecruiting
-
University Hospital, GrenobleCompletedVentilator Acquired PneumoniaFrance
-
Institut Jerome LejeuneRecruiting